Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review
Purpose Vincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive vincristine-induced neuropathy, possibly including both peripheral sensory and motor nerves, autonomic nervous functions, and the central nervous system. This...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology Jg. 84; H. 3; S. 471 - 485 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.09.2019
Springer Nature B.V |
| Schlagworte: | |
| ISSN: | 0344-5704, 1432-0843, 1432-0843 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Purpose
Vincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive vincristine-induced neuropathy, possibly including both peripheral sensory and motor nerves, autonomic nervous functions, and the central nervous system. This dose-limiting side-effect can diminish quality of life and, furthermore, cause discontinuation of vincristine treatment. The present review elucidates the current knowledge regarding vincristine-induced neuropathy in hematologic malignancies, focusing on neuropathy assessment, clinical and molecular predictive markers, drug–drug interference, prevention, and treatment.
Methods
This review is conducted by a systematic search strategy for the identification of relevant literature in the PubMed and Embase databases.
Results
No clinical parameters displayed convincing potential as predictors of vincristine-induced neuropathy; however, preexisting neuropathy was consistently reported to be associated with an increased risk of neurotoxicity. In contrast, molecular markers, including polymorphisms in genes involved in the pharmacodynamics and pharmacokinetics of vincristine, displayed great potential as predictive markers of neuropathy incidence and severity. Furthermore, antifungal drugs, such as itraconazole and voriconazole, decrease the metabolism of vincristine and consequently lead to severe neuropathy when co-administered with vincristine, underscoring why fluconazole should be the antifungal drug of choice.
Conclusion
Reports from the 71 included studies clearly emphasize the lack of consistency in neuropathy assessment, grading systems, and reporting, making it difficult to interpret results between studies. Thus, truer clinical and molecular markers could emerge if the consistency of neuropathy detection and reporting increases by the use of conventional standardized neuropathy assessment tools and grading scales. |
|---|---|
| AbstractList | Purpose
Vincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive vincristine-induced neuropathy, possibly including both peripheral sensory and motor nerves, autonomic nervous functions, and the central nervous system. This dose-limiting side-effect can diminish quality of life and, furthermore, cause discontinuation of vincristine treatment. The present review elucidates the current knowledge regarding vincristine-induced neuropathy in hematologic malignancies, focusing on neuropathy assessment, clinical and molecular predictive markers, drug–drug interference, prevention, and treatment.
Methods
This review is conducted by a systematic search strategy for the identification of relevant literature in the PubMed and Embase databases.
Results
No clinical parameters displayed convincing potential as predictors of vincristine-induced neuropathy; however, preexisting neuropathy was consistently reported to be associated with an increased risk of neurotoxicity. In contrast, molecular markers, including polymorphisms in genes involved in the pharmacodynamics and pharmacokinetics of vincristine, displayed great potential as predictive markers of neuropathy incidence and severity. Furthermore, antifungal drugs, such as itraconazole and voriconazole, decrease the metabolism of vincristine and consequently lead to severe neuropathy when co-administered with vincristine, underscoring why fluconazole should be the antifungal drug of choice.
Conclusion
Reports from the 71 included studies clearly emphasize the lack of consistency in neuropathy assessment, grading systems, and reporting, making it difficult to interpret results between studies. Thus, truer clinical and molecular markers could emerge if the consistency of neuropathy detection and reporting increases by the use of conventional standardized neuropathy assessment tools and grading scales. PurposeVincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive vincristine-induced neuropathy, possibly including both peripheral sensory and motor nerves, autonomic nervous functions, and the central nervous system. This dose-limiting side-effect can diminish quality of life and, furthermore, cause discontinuation of vincristine treatment. The present review elucidates the current knowledge regarding vincristine-induced neuropathy in hematologic malignancies, focusing on neuropathy assessment, clinical and molecular predictive markers, drug–drug interference, prevention, and treatment.MethodsThis review is conducted by a systematic search strategy for the identification of relevant literature in the PubMed and Embase databases.ResultsNo clinical parameters displayed convincing potential as predictors of vincristine-induced neuropathy; however, preexisting neuropathy was consistently reported to be associated with an increased risk of neurotoxicity. In contrast, molecular markers, including polymorphisms in genes involved in the pharmacodynamics and pharmacokinetics of vincristine, displayed great potential as predictive markers of neuropathy incidence and severity. Furthermore, antifungal drugs, such as itraconazole and voriconazole, decrease the metabolism of vincristine and consequently lead to severe neuropathy when co-administered with vincristine, underscoring why fluconazole should be the antifungal drug of choice.ConclusionReports from the 71 included studies clearly emphasize the lack of consistency in neuropathy assessment, grading systems, and reporting, making it difficult to interpret results between studies. Thus, truer clinical and molecular markers could emerge if the consistency of neuropathy detection and reporting increases by the use of conventional standardized neuropathy assessment tools and grading scales. Vincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive vincristine-induced neuropathy, possibly including both peripheral sensory and motor nerves, autonomic nervous functions, and the central nervous system. This dose-limiting side-effect can diminish quality of life and, furthermore, cause discontinuation of vincristine treatment. The present review elucidates the current knowledge regarding vincristine-induced neuropathy in hematologic malignancies, focusing on neuropathy assessment, clinical and molecular predictive markers, drug-drug interference, prevention, and treatment.PURPOSEVincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive vincristine-induced neuropathy, possibly including both peripheral sensory and motor nerves, autonomic nervous functions, and the central nervous system. This dose-limiting side-effect can diminish quality of life and, furthermore, cause discontinuation of vincristine treatment. The present review elucidates the current knowledge regarding vincristine-induced neuropathy in hematologic malignancies, focusing on neuropathy assessment, clinical and molecular predictive markers, drug-drug interference, prevention, and treatment.This review is conducted by a systematic search strategy for the identification of relevant literature in the PubMed and Embase databases.METHODSThis review is conducted by a systematic search strategy for the identification of relevant literature in the PubMed and Embase databases.No clinical parameters displayed convincing potential as predictors of vincristine-induced neuropathy; however, preexisting neuropathy was consistently reported to be associated with an increased risk of neurotoxicity. In contrast, molecular markers, including polymorphisms in genes involved in the pharmacodynamics and pharmacokinetics of vincristine, displayed great potential as predictive markers of neuropathy incidence and severity. Furthermore, antifungal drugs, such as itraconazole and voriconazole, decrease the metabolism of vincristine and consequently lead to severe neuropathy when co-administered with vincristine, underscoring why fluconazole should be the antifungal drug of choice.RESULTSNo clinical parameters displayed convincing potential as predictors of vincristine-induced neuropathy; however, preexisting neuropathy was consistently reported to be associated with an increased risk of neurotoxicity. In contrast, molecular markers, including polymorphisms in genes involved in the pharmacodynamics and pharmacokinetics of vincristine, displayed great potential as predictive markers of neuropathy incidence and severity. Furthermore, antifungal drugs, such as itraconazole and voriconazole, decrease the metabolism of vincristine and consequently lead to severe neuropathy when co-administered with vincristine, underscoring why fluconazole should be the antifungal drug of choice.Reports from the 71 included studies clearly emphasize the lack of consistency in neuropathy assessment, grading systems, and reporting, making it difficult to interpret results between studies. Thus, truer clinical and molecular markers could emerge if the consistency of neuropathy detection and reporting increases by the use of conventional standardized neuropathy assessment tools and grading scales.CONCLUSIONReports from the 71 included studies clearly emphasize the lack of consistency in neuropathy assessment, grading systems, and reporting, making it difficult to interpret results between studies. Thus, truer clinical and molecular markers could emerge if the consistency of neuropathy detection and reporting increases by the use of conventional standardized neuropathy assessment tools and grading scales. Vincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive vincristine-induced neuropathy, possibly including both peripheral sensory and motor nerves, autonomic nervous functions, and the central nervous system. This dose-limiting side-effect can diminish quality of life and, furthermore, cause discontinuation of vincristine treatment. The present review elucidates the current knowledge regarding vincristine-induced neuropathy in hematologic malignancies, focusing on neuropathy assessment, clinical and molecular predictive markers, drug-drug interference, prevention, and treatment. This review is conducted by a systematic search strategy for the identification of relevant literature in the PubMed and Embase databases. No clinical parameters displayed convincing potential as predictors of vincristine-induced neuropathy; however, preexisting neuropathy was consistently reported to be associated with an increased risk of neurotoxicity. In contrast, molecular markers, including polymorphisms in genes involved in the pharmacodynamics and pharmacokinetics of vincristine, displayed great potential as predictive markers of neuropathy incidence and severity. Furthermore, antifungal drugs, such as itraconazole and voriconazole, decrease the metabolism of vincristine and consequently lead to severe neuropathy when co-administered with vincristine, underscoring why fluconazole should be the antifungal drug of choice. Reports from the 71 included studies clearly emphasize the lack of consistency in neuropathy assessment, grading systems, and reporting, making it difficult to interpret results between studies. Thus, truer clinical and molecular markers could emerge if the consistency of neuropathy detection and reporting increases by the use of conventional standardized neuropathy assessment tools and grading scales. |
| Author | Madsen, Marie Lindhard Jensen, Paw Ejskjær, Niels Madsen, Jakob Due, Hanne Dybkær, Karen |
| Author_xml | – sequence: 1 givenname: Marie Lindhard surname: Madsen fullname: Madsen, Marie Lindhard organization: Department of Hematology, Aalborg University Hospital – sequence: 2 givenname: Hanne surname: Due fullname: Due, Hanne organization: Department of Hematology, Aalborg University Hospital, Department of Clinical Medicine, Aalborg University – sequence: 3 givenname: Niels surname: Ejskjær fullname: Ejskjær, Niels organization: Department of Clinical Medicine, Aalborg University, Steno Diabetes Center North Denmark, Aalborg University Hospital – sequence: 4 givenname: Paw surname: Jensen fullname: Jensen, Paw organization: Department of Hematology, Aalborg University Hospital, Clinical Cancer Research Center, Aalborg University Hospital – sequence: 5 givenname: Jakob surname: Madsen fullname: Madsen, Jakob organization: Department of Hematology, Aalborg University Hospital – sequence: 6 givenname: Karen surname: Dybkær fullname: Dybkær, Karen email: k.dybkaer@rn.dk organization: Department of Hematology, Aalborg University Hospital, Department of Clinical Medicine, Aalborg University, Clinical Cancer Research Center, Aalborg University Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31214762$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kUtvFDEQhC0URDaBP8ABjcSFy0D7MS8OSFGUAFIkLsmFi-Wxe3YdzdiL7Vm0_z6ebMIjh5wsub8qVXedkCPnHRLylsJHCtB8igCshRJoVwJvW1FWL8iKCs5KaAU_IivgIn82II7JSYy3ACAo56_IMaeMiqZmK_LzLG5Rp1j4odhZp4ONyTosrTOzRlM4nIPfqrTZF9YVG5xU8qNfW11MarRrp5y2GD8Xqoj7mJZxHgXcWfz9mrwc1BjxzcN7Sm4uL67Pv5VXP75-Pz-7KnUlIJUaheENbyuTU_V0yAuAMhWt-5oKAXXFAXujWgVCDR0aBqZDJXRXYw-VYfyUfDn4bud-QqPRpaBGuQ12UmEvvbLy_4mzG7n2O1nXLasang0-PBgE_2vGmORko8ZxVA79HCVjgouOCrag75-gt34OLq-3UKwWOXyXqXf_JvoT5fHsGWgPgA4-xoCD1Dbl0_kloB0lBbk0LA8Ny9ywvG9YVlnKnkgf3Z8V8YMoZtitMfyN_YzqDhwZubA |
| CitedBy_id | crossref_primary_10_1080_08880018_2022_2047849 crossref_primary_10_1080_10428194_2020_1742907 crossref_primary_10_1002_jat_4521 crossref_primary_10_1002_ibra_12086 crossref_primary_10_1016_j_neuint_2020_104841 crossref_primary_10_1182_bloodadvances_2024014695 crossref_primary_10_2174_1573412919666221123110420 crossref_primary_10_3390_cancers14030612 crossref_primary_10_3390_toxics9090218 crossref_primary_10_1007_s00210_022_02254_y crossref_primary_10_3390_ijms251910389 crossref_primary_10_1177_18758894251347128 crossref_primary_10_1016_j_jchromb_2025_124592 crossref_primary_10_1212_CON_0000000000000943 crossref_primary_10_3389_fphar_2023_1213763 crossref_primary_10_1016_j_jddst_2022_103545 crossref_primary_10_1080_17568919_2025_2546774 crossref_primary_10_1016_j_phoj_2023_06_004 crossref_primary_10_1093_jac_dkac060 crossref_primary_10_2147_PGPM_S460878 crossref_primary_10_1080_14740338_2024_2410436 crossref_primary_10_1111_jon_13255 crossref_primary_10_1124_dmd_123_001466 crossref_primary_10_1016_j_ejcped_2023_100017 crossref_primary_10_1186_s12885_020_6643_8 crossref_primary_10_3390_cancers13215346 crossref_primary_10_1007_s40262_023_01336_1 crossref_primary_10_1177_08258597211030382 crossref_primary_10_1002_mog2_46 crossref_primary_10_3390_jcm12175662 crossref_primary_10_3389_fimmu_2020_626687 crossref_primary_10_1016_j_intimp_2023_110046 crossref_primary_10_3390_bioengineering12010007 crossref_primary_10_1007_s00280_021_04302_5 crossref_primary_10_1182_blood_2019003690 crossref_primary_10_1111_cup_14199 crossref_primary_10_1097_MPH_0000000000002114 crossref_primary_10_1007_s00580_025_03666_x crossref_primary_10_1007_s11912_023_01449_7 crossref_primary_10_3390_ph17050609 crossref_primary_10_1007_s11916_025_01390_3 crossref_primary_10_1080_10428194_2024_2340051 crossref_primary_10_1007_s00520_024_08894_5 crossref_primary_10_1016_j_ejca_2021_09_014 crossref_primary_10_1016_j_ejmech_2021_113802 crossref_primary_10_1021_acschemneuro_4c00342 crossref_primary_10_1080_17425255_2021_1855141 crossref_primary_10_3390_ijms22084112 crossref_primary_10_1007_s00520_025_09365_1 crossref_primary_10_1002_jbt_70516 crossref_primary_10_1007_s11899_020_00585_2 crossref_primary_10_1007_s12288_025_02047_2 crossref_primary_10_1016_j_ijcard_2022_07_049 crossref_primary_10_2147_ORR_S339064 crossref_primary_10_3390_biom11050633 crossref_primary_10_7759_cureus_74213 crossref_primary_10_11603_ijmmr_2413_6077_2020_1_11503 crossref_primary_10_7759_cureus_18591 crossref_primary_10_1007_s11940_022_00716_5 crossref_primary_10_1016_j_bcp_2024_116070 crossref_primary_10_1146_annurev_pathol_030320_100822 crossref_primary_10_1111_coa_13778 crossref_primary_10_1007_s11060_025_05098_7 crossref_primary_10_3389_fcvm_2023_1243531 crossref_primary_10_1016_j_clml_2025_05_018 crossref_primary_10_1177_03000605231193823 crossref_primary_10_1016_j_jpba_2023_115578 crossref_primary_10_3390_cancers15071963 crossref_primary_10_3390_md20030188 crossref_primary_10_1007_s40487_021_00168_y crossref_primary_10_1155_2020_2679046 crossref_primary_10_1186_s12906_024_04441_1 crossref_primary_10_1007_s00204_022_03418_8 crossref_primary_10_3390_life14111500 crossref_primary_10_1080_1120009X_2023_2300217 crossref_primary_10_1093_jpp_rgae057 crossref_primary_10_1016_j_expneurol_2020_113519 |
| Cites_doi | 10.1007/BF00255486 10.1007/s00277-018-3437-z 10.1002/cncr.10397 10.1093/neuonc/nos203 10.1016/0022-510X(80)90179-3 10.1002/pbc.23039 10.1093/jac/dkr223 10.1007/BF02072486 10.2337/dc06-1499 10.1002/mus.24647 10.1002/cpt.506 10.2217/pgs-2016-0001 10.3109/10428194.2012.697560 10.1097/NCC.0b013e318299ad23 10.1016/0002-9394(76)90725-X 10.1002/1097-0142(19830201)51:3<423::AID-CNCR2820510311>3.0.CO;2-3 10.1016/j.ejca.2008.04.018 10.1016/j.ijporl.2006.09.001 10.1200/jco.2007.12.4784 10.1097/01.mph.0000165130.21539.a3 10.1007/BF01050259 10.3233/JPN-2009-0333 10.1097/mph.0000000000000910 10.12659/MSM.893142 10.1111/jns.12114 10.1016/j.ccr.2008.07.002 10.1016/S1040-8428(98)00023-7 10.1016/j.ejpn.2017.12.019 10.1002/pbc.21435 10.1097/00043426-200304000-00010 10.1080/0284186X.2017.1415462 10.1016/s1091853103003239 10.1159/000204462 10.1128/AAC.46.1.160-165.2002 10.1182/blood-2006-06-027714 10.1177/0883073814535495 10.1002/pbc.26525 10.1016/0163-7258(91)90004-6 10.1007/BF00313556 10.2169/internalmedicine.47.0701 10.1080/14737140.2017.1374856 10.1016/j.ejca.2005.02.012 10.1097/MPH.0b013e3181e01584 10.1046/j.1365-2141.2003.04430.x 10.2165/00003088-200038020-00002 10.1038/86882 10.1097/MPH.0000000000000825 10.1016/s1470-2045(10)70206-0 10.1007/PL00007853 10.1097/CAD.0b013e32833db89d 10.1038/s41397-017-0003-3 10.1007/s12098-010-0096-z 10.1007/s00520-016-3441-6 10.3109/08880018.2011.624163 10.1002/(SICI)1097-0142(19980101)82:1<200::AID-CNCR87>3.0.CO;2-5 10.1023/A:1008389607293 10.1136/bmj.1.6113.610 10.1200/jco.1996.14.3.935 10.1002/1097-0142(19890815)64:4<801::AID-CNCR2820640406>3.0.CO;2-E 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 10.2217/pgs.14.68 10.1002/pbc.26204 10.1111/j.1651-2227.2001.tb03257.x 10.1097/FPC.0000000000000191 10.1001/archneur.1992.00530340043016 10.1002/neu.480110304 10.1007/s11136-010-9670-0 10.7326/0003-4819-151-4-200908180-00135 10.1007/s00432-003-0524-9 10.1002/cncr.20071 10.1002/pbc.25384 10.1212/01.wnl.0000154642.45474.28 10.1007/bf02759902 10.1097/MPH.0b013e3181e9038d 10.1007/s00520-012-1591-8 10.3816/CLML.2010.n.025 10.1007/s00520-010-1043-2 10.1136/bmj.1.6071.1251 10.1046/j.1365-2257.1998.00103.x 10.1124/dmd.106.009902 10.1002/1097-0142(19940515)73:10<2515::AID-CNCR2820731011>3.0.CO;2-G 10.1007/s00520-013-1981-6 10.1177/1078155214553143 10.1001/archinte.1973.03650110061013 10.1182/blood-2006-10-054528 10.1097/COC.0b013e3181e1d0c0 10.1001/jama.2015.0894 10.1007/BF01697985 10.1002/pbc.26471 10.1111/j.1529-8027.2009.00230.x 10.1002/cpt.1179 10.1177/0883073813491829 10.1016/j.leukres.2010.01.026 10.1002/1097-0142(19810515)47:10<2404::AID-CNCR2820471014>3.0.CO;2-2 10.1016/1040-8428(93)90006-P 10.1007/s00520-017-3780-y 10.1016/j.jaapos.2003.07.010 10.14740/jocmr1856w 10.4103/1817-1745.154358 10.1002/pbc.26854 10.1097/MPH.0000000000001220 10.1111/j.1529-8027.2007.00141.x 10.1002/pbc.22845 10.1007/BF00179439 10.3928/01913913-20150629-01 10.1016/j.spen.2012.02.011 10.1007/s00277-015-2514-9 10.1097/nrl.0000000000000105 10.17724/jicna.2017.75 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2019 Cancer Chemotherapy and Pharmacology is a copyright of Springer, (2019). All Rights Reserved. © 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2019 – notice: Cancer Chemotherapy and Pharmacology is a copyright of Springer, (2019). All Rights Reserved. © 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1007/s00280-019-03884-5 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central (New) (NC LIVE) ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Oncogenes and Growth Factors Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1432-0843 |
| EndPage | 485 |
| ExternalDocumentID | PMC6682573 31214762 10_1007_s00280_019_03884_5 |
| Genre | Systematic Review Journal Article |
| GroupedDBID | --- -53 -56 -5G -BR -EM -~C .86 .VR 06C 06D 0R~ 0VY 1N0 203 29B 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2~H 30V 36B 4.4 406 408 409 40D 40E 5GY 5RE 5VS 67Z 6NX 6PF 78A 7X7 88E 8AO 8C1 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANZL AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABUWG ABUWZ ABWNU ABXPI ACAOD ACDTI ACGFS ACHSB ACHVE ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEFQL AEGAL AEGNC AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFJLC AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BDATZ BENPR BGNMA BPHCQ BSONS BVXVI C6C CCPQU CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMB EMOBN ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KPH LAS LLZTM M1P M4Y MA- MK0 N9A NB0 NPVJJ NQJWS NU0 O93 O9G O9I O9J OAM P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV RNS ROL RPX RRX RSV S16 S27 S37 S3B SAP SBL SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 Z7U Z82 Z83 Z87 Z8O Z8V Z8W Z91 ZMTXR ZOVNA ~EX ~KM -Y2 .GJ 1SB 2.D 28- 2P1 2VQ 3O- 53G 5QI AANXM AAPKM AARHV AAYTO AAYXX ABBRH ABDBE ABFSG ABQSL ABRTQ ABULA ACBXY ACSTC ACUDM ADHKG AEBTG AEFIE AEKMD AEZWR AFDYV AFDZB AFEXP AFFHD AFFNX AFHIU AFOHR AGGDS AGQPQ AHPBZ AHWEU AIXLP AJBLW ATHPR AYFIA BBWZM CAG CITATION COF EN4 GRRUI H13 KOW N2Q NDZJH O9- PHGZM PHGZT PJZUB PPXIY R4E RNI RZK S1Z S26 S28 SCLPG SDE T16 Y6R ZGI CGR CUY CVF ECM EIF NPM RIG 3V. 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c540t-ce4d37385d312b1f1430ad516b614406530ebda8a04af9ed20d9ea4c96eb05d23 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 91 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000478903100002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0344-5704 1432-0843 |
| IngestDate | Tue Nov 04 02:00:00 EST 2025 Fri Sep 05 06:11:58 EDT 2025 Sat Nov 08 14:35:16 EST 2025 Mon Jul 21 06:05:01 EDT 2025 Tue Nov 18 22:34:20 EST 2025 Sat Nov 29 04:45:34 EST 2025 Fri Feb 21 02:33:15 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Biomarkers Vincristine-induced neuropathy Neurotoxicity Hematologic malignancies Vincristine |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c540t-ce4d37385d312b1f1430ad516b614406530ebda8a04af9ed20d9ea4c96eb05d23 |
| Notes | ObjectType-Article-1 ObjectType-Evidence Based Healthcare-3 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://link.springer.com/10.1007/s00280-019-03884-5 |
| PMID | 31214762 |
| PQID | 2242644309 |
| PQPubID | 48447 |
| PageCount | 15 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6682573 proquest_miscellaneous_2243491423 proquest_journals_2242644309 pubmed_primary_31214762 crossref_citationtrail_10_1007_s00280_019_03884_5 crossref_primary_10_1007_s00280_019_03884_5 springer_journals_10_1007_s00280_019_03884_5 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-09-01 |
| PublicationDateYYYYMMDD | 2019-09-01 |
| PublicationDate_xml | – month: 09 year: 2019 text: 2019-09-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
| PublicationTitle | Cancer chemotherapy and pharmacology |
| PublicationTitleAbbrev | Cancer Chemother Pharmacol |
| PublicationTitleAlternate | Cancer Chemother Pharmacol |
| PublicationYear | 2019 |
| Publisher | Springer Berlin Heidelberg Springer Nature B.V |
| Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V |
| References | Broyl, Corthals, Jongen, van der Holt, Kuiper, de Knegt, van Duin, el Jarari, Bertsch, Lokhorst, Durie, Goldschmidt, Sonneveld (CR58) 2010; 11 Wang, Lew, Casciano, Clement, Johnson (CR110) 2002; 46 Takahashi, Kameoka, Yamanaka, Ubukawa, Saito, Fujishima, Fujishima, Saito, Hirokawa, Scott, Sawada (CR70) 2008; 47 Bohme, Ganser, Hoelzer (CR72) 1995; 71 Akbayram, Akgun, Dogan, Sayin, Caksen, Oner (CR82) 2010; 77 Brunello, Kapoor, Extermann (CR47) 2011; 34 Anghelescu, Faughnan, Jeha, Relling, Hinds, Sandlund, Cheng, Pei, Hankins, Pauley, Pui (CR44) 2011; 57 Renbarger, McCammack, Rouse, Hall (CR57) 2008; 50 Miller, Hoogstraten, Staquet, Winkler (CR97) 1981; 47 Kanbayashi, Hosokawa, Okamoto, Konishi, Otsuji, Yoshikawa, Takagi, Taniwaki (CR49) 2010; 21 Re, Schwenk, Hegener, Bamborschke, Diehl, Tesch (CR52) 2000; 11 Riga, Psarommatis, Korres, Varvutsi, Giotakis, Apostolopoulos, Ferekidis (CR21) 2007; 71 Morth, Valachis, Sabaa, Molin, Flogegard, Enblad (CR7) 2018; 97 Lash, Williams, Marsh, Crithchley, Hodgkins, MacKie (CR17) 2004; 8 Chauvenet, Shashi, Selsky, Morgan, Kurtzberg, Bell (CR51) 2003; 25 Toker, Yenice, Ogut (CR18) 2004; 8 Scheithauer, Ludwig, Maida (CR24) 1985; 3 Gilchrist (CR100) 2012; 19 Whittaker, Griffith (CR23) 1977; 1 Le-Rademacher, Kanwar, Seisler, Pachman, Qin, Abyzov, Ruddy, Banck, Lavoie Smith, Dorsey, Aaronson, Sloan, Loprinzi, Beutler (CR43) 2017; 25 Moghrabi, Levy, Asselin, Barr, Clavell, Hurwitz, Samson, Schorin, Dalton, Lipshultz, Neuberg, Gelber, Cohen, Sallan, Silverman (CR29) 2007; 109 Kellie, Barbaric, Koopmans, Earl, Carr, de Graaf (CR28) 2002; 94 CR41 Ceppi, Langlois-Pelletier, Gagne, Rousseau, Ciolino, De Lorenzo, Kevin, Cijov, Sallan, Silverman, Neuberg, Kutok, Sinnett, Laverdiere, Krajinovic (CR60) 2014; 15 Guiheneuc, Ginet, Groleau, Rojouan (CR37) 1980; 45 Smitherman, Faircloth, Deal, Troy, Gold (CR69) 2017 Ryan, Emami (CR80) 1983; 51 Watkins, Griffin (CR88) 1978; 1 Kavcic, Koritnik, Krzan, Velikonja, Prelog, Stefanovic, Debeljak, Jazbec (CR9) 2017; 39 Wright, Amstutz, Drogemoller, Shih, Rassekh, Hayden, Carleton, Ross (CR68) 2018 van Schie, Bruggemann, Hoogerbrugge, te Loo (CR76) 2011; 66 Cavaletti, Frigeni, Lanzani, Piatti, Rota, Briani, Zara, Plasmati, Pastorelli, Caraceni, Pace, Manicone, Lissoni, Colombo, Bianchi, Zanna (CR99) 2007; 12 Latiff, Kamal, Jahendran, Alias, Goh, Syed Zakaria, Jamal (CR22) 2010; 32 Ibañez-Juliá, Berzero, Reyes-Botero, Maisonobe, Lenglet, Slim, Louis, Balaguer, Sanson, Le Guern, Latour, Ricard, Stojkovic, Psimaras (CR50) 2018; 57 Vainionpaa (CR95) 1993; 152 Mahajan, Ikeda, Myers, Baldini (CR20) 1981; 47 Gilchrist, Marais, Tanner (CR34) 2014; 22 Bakogeorgos, Georgoulias (CR101) 2017; 17 Hussain, Wozniak, Edelstein (CR102) 1993; 14 Verstappen, Koeppen, Heimans, Huijgens, Scheulen, Strumberg, Kiburg, Postma (CR91) 2005; 64 Utsu, Takaishi, Inagaki, Arai, Yuasa, Masuda, Matsuura, Aotsuka, Wakita (CR6) 2016; 95 Gutierrez-Camino, Martin-Guerrero, Lopez-Lopez, Echebarria-Barona, Zabalza, Ruiz, Guerra-Merino, Garcia-Orad (CR63) 2016; 26 Adhikari, Dongol, Hewett, Shah (CR12) 2014; 34 Cheung, Hicks, Leitch (CR77) 2010; 10 Diouf, Crews, Lew, Pei, Cheng, Bao, Zheng, Yang, Fan, Wheeler, Wing, Delaney, Komatsu, Paugh, McCorkle, Lu, Winick, Carroll, Loh, Hunger, Devidas, Pui, Dolan, Relling, Evans (CR61) 2015; 313 Lopez-Lopez, Gutierrez-Camino, Astigarraga, Navajas, Echebarria-Barona, Garcia-Miguel, Garcia de Andoin, Lobo, Guerra-Merino, Martin-Guerrero, Garcia-Orad (CR65) 2016; 17 Kishi, Cheng, French, Pei, Das, Cook, Hijiya, Rizzari, Rosner, Frudakis, Pui, Evans, Relling (CR56) 2007; 109 Postma, Aaronson, Heimans, Muller, Hildebrand, Delattre, Hoang-Xuan, Lanteri-Minet, Grant, Huddart, Moynihan, Maher, Lucey (CR42) 2005; 41 Hirvonen, Salmi, Heinonen, Antila, Valimaki (CR36) 1989; 64 Tomiwa, Mikawa, Hazama, Yazawa, Hosoya, Ohya, Nishimura (CR26) 1983; 229 Gidding, Kellie, Kamps, de Graaf (CR2) 1999; 29 Tay, Lee, Ong, Goh, Ariffin, Fong (CR89) 2017 Gilchrist, Tanner, Ness (CR96) 2017; 64 Trotti, Colevas, Setser, Basch (CR98) 2007; 25 Wolf, Barton, Kottschade, Grothey, Loprinzi (CR103) 2008; 44 Chan, Worth, Ochs (CR8) 1980; 11 Desai, Van den Berg, Bridges, Shanks (CR46) 1982; 8 van Kooten, van Diemen, Groenhout, Huijgens, Ossenkoppele, Nauta, Heimans (CR81) 1992; 49 Teusink, Ragucci, Shatat, Kalpatthi (CR73) 2012; 29 Postma, Benard, Huijgens, Ossenkoppele, Heimans (CR90) 1993; 15 How, Blattner, Fowler, Wang-Gillam, Schindler (CR25) 2016; 21 Weintraub, Adde, Venzon, Shad, Horak, Neely, Seibel, Gootenberg, Arndt, Nieder, Magrath (CR79) 1996; 14 Bay, Yilmaz, Yilmaz, Oner (CR15) 2006; 73 Jain, Gulati, Toteja, Bakhshi, Seth, Pandey (CR45) 2015; 30 Gillies, Hung, Fitzsimons, Soutar (CR74) 1998; 20 Harila-Saari, Vainionpää, Kovala, Tolonen, Lanning (CR87) 1998; 82 Venkatakrishnan, von Moltke, Greenblatt (CR109) 2000; 38 Ngamphaiboon, Sweeney, Wetzler, Wang (CR19) 2010; 34 Toopchizadeh, Barzegar, Rezamand, Feiz (CR38) 2009; 7 Gulliford, Charlton, Latinovic (CR106) 2006; 29 Gascoigne, Taylor (CR4) 2008; 14 Skiles, Chiang, Li, Martin, Smith, Olbara, Jones, Vik, Mostert, Abbink, Kaspers, Li, Njuguna, Sajdyk, Renbarger (CR67) 2018 Dennison, Kulanthaivel, Barbuch, Renbarger, Ehlhardt, Hall (CR107) 2006; 34 Weiser, Cabanillas, Konopleva, Thomas, Pierce, Escalante, Kantarjian, O’Brien (CR48) 2004; 100 Egbelakin, Ferguson, MacGill, Lehmann, Topletz, Quinney, Li, McCammack, Hall, Renbarger (CR59) 2011; 56 Sands, Ladas, Kelly, Weiner, Lin, Ndao, Dave, Vahdat, Bender (CR84) 2017; 25 Koeppen, Verstappen, Korte, Scheulen, Strumberg, Postma, Heimans, Huijgens, Kiburg, Renzing-Kohler, Diener (CR85) 2004; 130 El Hayek, Trad, Jamil (CR11) 2005; 27 Stock, Diouf, Crews, Pei, Cheng, Laumann, Mandrekar, Luger, Advani, Stone, Larson, Evans (CR62) 2017; 101 Gutierrez-Camino, Umerez, Martin-Guerrero, Garcia de Andoin, Santos, Sastre, Echebarria-Barona, Astigarraga, Navajas, Garcia-Orad (CR5) 2017 Quasthoff, Hartung (CR104) 2002; 249 Mokhtar, Shaaban, Elbarbary, Fayed (CR10) 2010; 32 Kamaluddin, McNally, Breatnach, O’Marcaigh, Webb, O’Dell, Scanlon, Butler, O’Meara (CR75) 2001; 90 Grisold, Cavaletti, Windebank (CR105) 2012; 14 Gilchrist, Tanner (CR33) 2013; 21 Courtemanche, Magot, Ollivier, Rialland, Leclair-Visonneau, Fayet, Camdessanche, Pereon (CR39) 2015; 52 Palkar, Nair, Desai, Potdar, Shinde (CR14) 2015; 52 Aplenc, Glatfelter, Han, Rappaport, La, Cnaan, Blackwood, Lange, Rebbeck (CR55) 2003; 122 Sanderson, Kuwabara, Cogan (CR13) 1976; 81 Nikanjam, Sun, Albers, Mangalindin, Song, Vempaty, Sam, Capparelli (CR71) 2018; 40 Lavoie Smith, Li, Chiang, Thomas, Hutchinson, Wells, Ho, Skiles, Chakraborty, Bridges, Renbarger (CR93) 2015; 20 Moher, Liberati, Tetzlaff, Altman (CR31) 2009; 151 Kayilioglu, Kocak, Kan Karaer, Percin, Sal, Tekkesin, Isik, Oner, Belen, Yilmaz Keskin, Okur, Albayrak, Kaya, Pinarli, Yenicesu, Karadeniz, Oguz, Gursel (CR66) 2017; 39 Kuehl, Zhang, Lin, Lamba, Assem, Schuetz, Watkins, Daly, Wrighton, Hall, Maurel, Relling, Brimer, Yasuda, Venkataramanan, Strom, Thummel, Boguski, Schuetz (CR108) 2001; 27 Yang, Yu, Chen, Hu, Wang (CR1) 2015; 21 Ramchandren, Leonard, Mody, Donohue, Moyer, Hutchinson, Gurney (CR40) 2009; 14 Correia (CR3) 1991; 52 Lavoie Smith, Li, Hutchinson, Ho, Burnette, Wells, Bridges, Renbarger (CR35) 2013; 36 Robertson, Bhoopalam, Zelkowitz (CR27) 1973; 132 Okada, Hanafusa, Sakurada, Teraoka, Kujime, Abe, Shinohara, Kawazoe, Minakuchi (CR54) 2014; 6 Lieber, Blankenburg, Apel, Hirschfeld, Hernaiz Driever, Reindl (CR32) 2018; 22 Kautio, Haanpää, Kautiainen, Kalso, Saarto (CR30) 2011; 19 Haim, Epelbaum, Ben-Shahar, Yarnitsky, Simri, Robinson (CR92) 1994; 73 Kim, Park, Roh, Jeong, Kim, Park, Cho, So, Oh, Kim (CR94) 2010; 19 Sims (CR64) 2016; 22 Jain, Gulati, Seth, Bakhshi, Toteja, Pandey (CR86) 2014; 29 Bhushan, Bhargava, Kasundra, Shubhakaran, Sood (CR53) 2015; 10 Ezzat, Cheung, Hicks, Boro, Montaner, Lima, Harris, Leitch (CR78) 2012; 53 Soysal, Ferhanoglu, Bilir, Akman (CR16) 1993; 90 Bradfield, Sandler, Geller, Tamura, Krischer (CR83) 2015; 62 EM Lavoie Smith (3884_CR35) 2013; 36 A Bay (3884_CR15) 2006; 73 PA Sanderson (3884_CR13) 1976; 81 B Bhushan (3884_CR53) 2015; 10 P Kuehl (3884_CR108) 2001; 27 A Broyl (3884_CR58) 2010; 11 L Gilchrist (3884_CR100) 2012; 19 E Lopez-Lopez (3884_CR65) 2016; 17 CG Tay (3884_CR89) 2017 ZR Desai (3884_CR46) 1982; 8 JJ Correia (3884_CR3) 1991; 52 A Egbelakin (3884_CR59) 2011; 56 M Kavcic (3884_CR9) 2017; 39 HE Hirvonen (3884_CR36) 1989; 64 GM Mokhtar (3884_CR10) 2010; 32 LS Gilchrist (3884_CR33) 2013; 21 F Ceppi (3884_CR60) 2014; 15 A Brunello (3884_CR47) 2011; 34 M El Hayek (3884_CR11) 2005; 27 B Diouf (3884_CR61) 2015; 313 A Bohme (3884_CR72) 1995; 71 L Vainionpaa (3884_CR95) 1993; 152 GL Robertson (3884_CR27) 1973; 132 P Guiheneuc (3884_CR37) 1980; 45 E-j Wang (3884_CR110) 2002; 46 S Ramchandren (3884_CR40) 2009; 14 J How (3884_CR25) 2016; 21 TJ Postma (3884_CR90) 1993; 15 N Takahashi (3884_CR70) 2008; 47 M Riga (3884_CR21) 2007; 71 LS Gilchrist (3884_CR96) 2017; 64 ZA Latiff (3884_CR22) 2010; 32 W Grisold (3884_CR105) 2012; 14 SM Watkins (3884_CR88) 1978; 1 TJ Postma (3884_CR42) 2005; 41 A Gutierrez-Camino (3884_CR63) 2016; 26 EM Lavoie Smith (3884_CR93) 2015; 20 MJ Ibañez-Juliá (3884_CR50) 2018; 57 D Re (3884_CR52) 2000; 11 JB Dennison (3884_CR107) 2006; 34 LS Gilchrist (3884_CR34) 2014; 22 S Adhikari (3884_CR12) 2014; 34 GEB Wright (3884_CR68) 2018 AL Kautio (3884_CR30) 2011; 19 T Soysal (3884_CR16) 1993; 90 RM van Schie (3884_CR76) 2011; 66 P Jain (3884_CR86) 2014; 29 V Toopchizadeh (3884_CR38) 2009; 7 JR Ryan (3884_CR80) 1983; 51 S Akbayram (3884_CR82) 2010; 77 S Koeppen (3884_CR85) 2004; 130 A Gutierrez-Camino (3884_CR5) 2017 J Gillies (3884_CR74) 1998; 20 HM Ezzat (3884_CR78) 2012; 53 D Moher (3884_CR31) 2009; 151 BJ Kim (3884_CR94) 2010; 19 JL Skiles (3884_CR67) 2018 B van Kooten (3884_CR81) 1992; 49 H Kayilioglu (3884_CR66) 2017; 39 JA Whittaker (3884_CR23) 1977; 1 C Morth (3884_CR7) 2018; 97 SJ Kellie (3884_CR28) 2002; 94 MA Weiser (3884_CR48) 2004; 100 AR Chauvenet (3884_CR51) 2003; 25 CC Verstappen (3884_CR91) 2005; 64 M Weintraub (3884_CR79) 1996; 14 L Yang (3884_CR1) 2015; 21 AB Miller (3884_CR97) 1981; 47 SC Lash (3884_CR17) 2004; 8 P Jain (3884_CR45) 2015; 30 AC Teusink (3884_CR73) 2012; 29 M Kamaluddin (3884_CR75) 2001; 90 DL Anghelescu (3884_CR44) 2011; 57 Y Utsu (3884_CR6) 2016; 95 S Quasthoff (3884_CR104) 2002; 249 K Tomiwa (3884_CR26) 1983; 229 A Moghrabi (3884_CR29) 2007; 109 N Okada (3884_CR54) 2014; 6 N Ngamphaiboon (3884_CR19) 2010; 34 J Le-Rademacher (3884_CR43) 2017; 25 RP Sims (3884_CR64) 2016; 22 S Lieber (3884_CR32) 2018; 22 H Courtemanche (3884_CR39) 2015; 52 Y Kanbayashi (3884_CR49) 2010; 21 G Cavaletti (3884_CR99) 2007; 12 SL Mahajan (3884_CR20) 1981; 47 M Bakogeorgos (3884_CR101) 2017; 17 S Sands (3884_CR84) 2017; 25 W Scheithauer (3884_CR24) 1985; 3 AB Smitherman (3884_CR69) 2017 K Venkatakrishnan (3884_CR109) 2000; 38 S Wolf (3884_CR103) 2008; 44 W Stock (3884_CR62) 2017; 101 N Haim (3884_CR92) 1994; 73 3884_CR41 JL Renbarger (3884_CR57) 2008; 50 M Hussain (3884_CR102) 1993; 14 AH Palkar (3884_CR14) 2015; 52 R Aplenc (3884_CR55) 2003; 122 A Trotti (3884_CR98) 2007; 25 CE Gidding (3884_CR2) 1999; 29 M Nikanjam (3884_CR71) 2018; 40 SM Bradfield (3884_CR83) 2015; 62 E Toker (3884_CR18) 2004; 8 S Kishi (3884_CR56) 2007; 109 KE Gascoigne (3884_CR4) 2008; 14 MC Gulliford (3884_CR106) 2006; 29 AH Harila-Saari (3884_CR87) 1998; 82 MC Cheung (3884_CR77) 2010; 10 SY Chan (3884_CR8) 1980; 11 |
| References_xml | – volume: 8 start-page: 211 issue: 2 year: 1982 end-page: 214 ident: CR46 article-title: Can severe vincristine neurotoxicity be prevented? publication-title: Cancer Chemother Pharmacol doi: 10.1007/BF00255486 – volume: 97 start-page: 2129 issue: 11 year: 2018 end-page: 2135 ident: CR7 article-title: Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome? publication-title: Ann Hematol doi: 10.1007/s00277-018-3437-z – volume: 94 start-page: 1815 issue: 6 year: 2002 end-page: 1820 ident: CR28 article-title: Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: a surrogate marker of brain penetration publication-title: Cancer doi: 10.1002/cncr.10397 – volume: 14 start-page: 45 issue: Suppl. 4 year: 2012 end-page: 54 ident: CR105 article-title: Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention publication-title: Neuro-oncology doi: 10.1093/neuonc/nos203 – volume: 45 start-page: 355 issue: 2–3 year: 1980 end-page: 366 ident: CR37 article-title: Early phase of vincristine neuropathy in man. Electrophysiological evidence for a dying-back phenomenon, with transitory enhancement of spinal transmission of the monosynaptic reflex publication-title: J Neurol Sci doi: 10.1016/0022-510X(80)90179-3 – volume: 57 start-page: 1147 issue: 7 year: 2011 end-page: 1153 ident: CR44 article-title: Neuropathic pain during treatment for childhood acute lymphoblastic leukemia publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.23039 – volume: 66 start-page: 1853 issue: 8 year: 2011 end-page: 1856 ident: CR76 article-title: Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkr223 – volume: 152 start-page: 115 issue: 2 year: 1993 end-page: 119 ident: CR95 article-title: Clinical neurological findings of children with acute lymphoblastic leukaemia at diagnosis and during treatment publication-title: Eur J Pediatr doi: 10.1007/BF02072486 – volume: 29 start-page: 2728 issue: 12 year: 2006 end-page: 2729 ident: CR106 article-title: Risk of diabetes associated with prescribed glucocorticoids in a large population publication-title: Diabetes Care doi: 10.2337/dc06-1499 – volume: 52 start-page: 981 issue: 6 year: 2015 end-page: 985 ident: CR39 article-title: Vincristine-induced neuropathy: atypical electrophysiological patterns in children publication-title: Muscle Nerve doi: 10.1002/mus.24647 – volume: 101 start-page: 391 issue: 3 year: 2017 end-page: 395 ident: CR62 article-title: An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.506 – volume: 17 start-page: 731 issue: 7 year: 2016 end-page: 741 ident: CR65 article-title: Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia publication-title: Pharmacogenomics doi: 10.2217/pgs-2016-0001 – volume: 53 start-page: 2390 issue: 12 year: 2012 end-page: 2396 ident: CR78 article-title: Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma publication-title: Leukemia Lymphoma doi: 10.3109/10428194.2012.697560 – volume: 36 start-page: E49 issue: 5 year: 2013 end-page: E60 ident: CR35 article-title: Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia publication-title: Cancer Nurs doi: 10.1097/NCC.0b013e318299ad23 – volume: 81 start-page: 146 issue: 2 year: 1976 end-page: 150 ident: CR13 article-title: Optic neuropathy presumably caused by vincristine therapy publication-title: Am J Ophthalmol doi: 10.1016/0002-9394(76)90725-X – volume: 51 start-page: 423 issue: 3 year: 1983 end-page: 425 ident: CR80 article-title: Vincristine neurotoxicity with residual equinocavus deformity in children with acute leukemia publication-title: Cancer doi: 10.1002/1097-0142(19830201)51:3<423::AID-CNCR2820510311>3.0.CO;2-3 – volume: 44 start-page: 1507 issue: 11 year: 2008 end-page: 1515 ident: CR103 article-title: Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies publication-title: Eur J Cancer doi: 10.1016/j.ejca.2008.04.018 – volume: 71 start-page: 63 issue: 1 year: 2007 end-page: 69 ident: CR21 article-title: Neurotoxicity of vincristine on the medial olivocochlear bundle publication-title: Int J Pediatr Otorhinolaryngol doi: 10.1016/j.ijporl.2006.09.001 – volume: 25 start-page: 5121 issue: 32 year: 2007 end-page: 5127 ident: CR98 article-title: Patient-reported outcomes and the evolution of adverse event reporting in oncology publication-title: J Clin Oncol doi: 10.1200/jco.2007.12.4784 – volume: 27 start-page: 286 issue: 5 year: 2005 end-page: 287 ident: CR11 article-title: Vincristine-induced urinary bladder paralysis publication-title: J Pediatr Hematol Oncol doi: 10.1097/01.mph.0000165130.21539.a3 – volume: 15 start-page: 23 issue: 1 year: 1993 end-page: 27 ident: CR90 article-title: Long-term effects of vincristine on the peripheral nervous system publication-title: J Neurooncol doi: 10.1007/BF01050259 – volume: 7 start-page: 351 issue: 4 year: 2009 end-page: 356 ident: CR38 article-title: Electrophysiological consequences of vincristine contained chemotherapy in children: a cohort study publication-title: J Pediatr Neurol doi: 10.3233/JPN-2009-0333 – volume: 39 start-page: 458 issue: 6 year: 2017 end-page: 462 ident: CR66 article-title: Association of CYP3A5 expression and vincristine neurotoxicity in pediatric malignancies in Turkish population publication-title: J Pediatr Hematol Oncol doi: 10.1097/mph.0000000000000910 – volume: 21 start-page: 1656 year: 2015 end-page: 1661 ident: CR1 article-title: Clinical analysis of adverse drug reactions between vincristine and triazoles in children with acute lymphoblastic leukemia publication-title: Med Sci Monit doi: 10.12659/MSM.893142 – volume: 20 start-page: 37 issue: 1 year: 2015 end-page: 46 ident: CR93 article-title: Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia publication-title: J Periph Nerv Syst doi: 10.1111/jns.12114 – volume: 14 start-page: 111 issue: 2 year: 2008 end-page: 122 ident: CR4 article-title: Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs publication-title: Cancer Cell doi: 10.1016/j.ccr.2008.07.002 – volume: 29 start-page: 267 issue: 3 year: 1999 end-page: 287 ident: CR2 article-title: Vincristine revisited publication-title: Crit Rev Oncol Hematol doi: 10.1016/S1040-8428(98)00023-7 – volume: 22 start-page: 457 issue: 3 year: 2018 end-page: 469 ident: CR32 article-title: Small-fiber neuropathy and pain sensitization in survivors of pediatric acute lymphoblastic leukemia publication-title: Eur J Paediatr Neurol EJPN doi: 10.1016/j.ejpn.2017.12.019 – volume: 50 start-page: 769 issue: 4 year: 2008 end-page: 771 ident: CR57 article-title: Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.21435 – volume: 25 start-page: 316 issue: 4 year: 2003 end-page: 320 ident: CR51 article-title: Vincristine-induced neuropathy as the initial presentation of Charcot–Marie–Tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study publication-title: J Pediatr Hematol Oncol doi: 10.1097/00043426-200304000-00010 – volume: 57 start-page: 403 issue: 3 year: 2018 end-page: 411 ident: CR50 article-title: Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability publication-title: Acta Oncol doi: 10.1080/0284186X.2017.1415462 – volume: 8 start-page: 69 issue: 1 year: 2004 end-page: 71 ident: CR18 article-title: Isolated abducens nerve palsy induced by vincristine therapy publication-title: J AAPOS doi: 10.1016/s1091853103003239 – volume: 90 start-page: 209 issue: 4 year: 1993 end-page: 210 ident: CR16 article-title: Oculomotor nerve palsy associated with vincristine treatment publication-title: Acta Haematol doi: 10.1159/000204462 – volume: 46 start-page: 160 issue: 1 year: 2002 end-page: 165 ident: CR110 article-title: Interaction of common azole antifungals with P glycoprotein publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.46.1.160-165.2002 – volume: 109 start-page: 896 issue: 3 year: 2007 end-page: 904 ident: CR29 article-title: Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia publication-title: Blood doi: 10.1182/blood-2006-06-027714 – volume: 30 start-page: 786 issue: 6 year: 2015 end-page: 788 ident: CR45 article-title: Serum alpha tocopherol, vitamin B12, and folate levels in childhood acute lymphoblastic leukemia survivors with and without neuropathy publication-title: J Child Neurol doi: 10.1177/0883073814535495 – year: 2017 ident: CR69 article-title: Vincristine toxicity with co-administration of fluconazole during induction therapy for pediatric acute lymphoblastic leukemia publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.26525 – volume: 52 start-page: 127 issue: 2 year: 1991 end-page: 147 ident: CR3 article-title: Effects of antimitotic agents on tubulin–nucleotide interactions publication-title: Pharmacol Ther doi: 10.1016/0163-7258(91)90004-6 – volume: 229 start-page: 267 issue: 4 year: 1983 end-page: 272 ident: CR26 article-title: Syndrome of inappropriate secretion of antidiuretic hormone caused by vincristine therapy: a case report of the neuropathology publication-title: J Neurol doi: 10.1007/BF00313556 – volume: 47 start-page: 651 issue: 7 year: 2008 end-page: 653 ident: CR70 article-title: Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma publication-title: Intern Med (Tokyo, Japan) doi: 10.2169/internalmedicine.47.0701 – volume: 17 start-page: 1045 issue: 11 year: 2017 end-page: 1060 ident: CR101 article-title: Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy publication-title: Expert Rev Anticancer Ther doi: 10.1080/14737140.2017.1374856 – volume: 41 start-page: 1135 issue: 8 year: 2005 end-page: 1139 ident: CR42 article-title: The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20 publication-title: Eur J Cancer (Oxford, England: 1990) doi: 10.1016/j.ejca.2005.02.012 – volume: 32 start-page: 407 issue: 5 year: 2010 end-page: 410 ident: CR22 article-title: Vincristine-induced vocal cord palsy: case report and review of the literature publication-title: J Pediatr Hematol Oncol doi: 10.1097/MPH.0b013e3181e01584 – volume: 122 start-page: 240 issue: 2 year: 2003 end-page: 244 ident: CR55 article-title: CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia publication-title: Br J Haematol doi: 10.1046/j.1365-2141.2003.04430.x – volume: 38 start-page: 111 issue: 2 year: 2000 end-page: 180 ident: CR109 article-title: Effects of the antifungal agents on oxidative drug metabolism: clinical relevance publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200038020-00002 – volume: 27 start-page: 383 issue: 4 year: 2001 end-page: 391 ident: CR108 article-title: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression publication-title: Nat Genet doi: 10.1038/86882 – volume: 39 start-page: 266 issue: 4 year: 2017 end-page: 271 ident: CR9 article-title: Electrophysiological studies to detect peripheral neuropathy in children treated with vincristine publication-title: J Pediatr Hematol Oncol doi: 10.1097/MPH.0000000000000825 – volume: 11 start-page: 1057 issue: 11 year: 2010 end-page: 1065 ident: CR58 article-title: Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial publication-title: Lancet Oncol doi: 10.1016/s1470-2045(10)70206-0 – volume: 249 start-page: 9 issue: 1 year: 2002 end-page: 17 ident: CR104 article-title: Chemotherapy-induced peripheral neuropathy publication-title: J Neurol doi: 10.1007/PL00007853 – volume: 21 start-page: 877 issue: 9 year: 2010 end-page: 881 ident: CR49 article-title: Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis publication-title: Anticancer Drugs doi: 10.1097/CAD.0b013e32833db89d – year: 2017 ident: CR5 article-title: Mir-pharmacogenetics of vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia publication-title: Pharmacogenom J doi: 10.1038/s41397-017-0003-3 – volume: 77 start-page: 681 issue: 6 year: 2010 end-page: 683 ident: CR82 article-title: Use of pyridoxine and pyridostigmine in children with vincristine-induced neuropathy publication-title: Indian J Pediatr doi: 10.1007/s12098-010-0096-z – volume: 25 start-page: 701 issue: 3 year: 2017 end-page: 708 ident: CR84 article-title: Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer publication-title: Support Care Cancer doi: 10.1007/s00520-016-3441-6 – volume: 29 start-page: 62 issue: 1 year: 2012 end-page: 67 ident: CR73 article-title: Potentiation of vincristine toxicity with concomitant fluconazole prophylaxis in children with acute lymphoblastic leukemia publication-title: Pediatr Hematol Oncol doi: 10.3109/08880018.2011.624163 – volume: 82 start-page: 200 issue: 1 year: 1998 end-page: 207 ident: CR87 article-title: Nerve lesions after therapy for childhood acute lymphoblastic leukemia publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19980101)82:1<200::AID-CNCR87>3.0.CO;2-5 – volume: 11 start-page: 217 issue: 2 year: 2000 end-page: 220 ident: CR52 article-title: Guillain-Barre syndrome in a patient with non-Hodgkin’s lymphoma publication-title: Ann Oncol doi: 10.1023/A:1008389607293 – volume: 1 start-page: 610 issue: 6113 year: 1978 end-page: 612 ident: CR88 article-title: High incidence of vincristine-induced neuropathy in lymphomas publication-title: BMJ doi: 10.1136/bmj.1.6113.610 – ident: CR41 – volume: 14 start-page: 935 issue: 3 year: 1996 end-page: 940 ident: CR79 article-title: Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine publication-title: J Clin Oncol doi: 10.1200/jco.1996.14.3.935 – volume: 64 start-page: 801 issue: 4 year: 1989 end-page: 805 ident: CR36 article-title: Vincristine treatment of acute lymphoblastic leukemia induces transient autonomic cardioneuropathy publication-title: Cancer doi: 10.1002/1097-0142(19890815)64:4<801::AID-CNCR2820640406>3.0.CO;2-E – volume: 47 start-page: 207 issue: 1 year: 1981 end-page: 214 ident: CR97 article-title: Reporting results of cancer treatment publication-title: Cancer doi: 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 – volume: 15 start-page: 1105 issue: 8 year: 2014 end-page: 1116 ident: CR60 article-title: Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia publication-title: Pharmacogenomics doi: 10.2217/pgs.14.68 – volume: 64 start-page: 180 issue: 1 year: 2017 end-page: 187 ident: CR96 article-title: Short-term recovery of chemotherapy-induced peripheral neuropathy after treatment for pediatric non-CNS cancer publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.26204 – volume: 90 start-page: 1204 issue: 10 year: 2001 end-page: 1207 ident: CR75 article-title: Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies publication-title: Acta Paediatr doi: 10.1111/j.1651-2227.2001.tb03257.x – volume: 26 start-page: 100 issue: 2 year: 2016 end-page: 102 ident: CR63 article-title: Lack of association of the CEP72 RS924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population publication-title: Pharmacogenet Genom doi: 10.1097/FPC.0000000000000191 – volume: 49 start-page: 1027 issue: 10 year: 1992 end-page: 1031 ident: CR81 article-title: A pilot study on the influence of a corticotropin (4–9) analogue on Vinca alkaloid-induced neuropathy publication-title: Arch Neurol doi: 10.1001/archneur.1992.00530340043016 – volume: 11 start-page: 251 issue: 3 year: 1980 end-page: 264 ident: CR8 article-title: Block of axoplasmic transport in vitro by vinca alkaloids publication-title: J Neurobiol doi: 10.1002/neu.480110304 – volume: 34 start-page: 6731 issue: 11 year: 2014 end-page: 6733 ident: CR12 article-title: Vincristine-induced blindness: a case report and review of literature publication-title: Anticancer Res – volume: 19 start-page: 1097 issue: 8 year: 2010 end-page: 1103 ident: CR94 article-title: Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma publication-title: Q Life Res doi: 10.1007/s11136-010-9670-0 – volume: 151 start-page: 264 issue: 4 year: 2009 end-page: 269 ident: CR31 article-title: Preferred reporting items for systematic reviews and meta-analyses: the prisma statement publication-title: Ann Intern Med doi: 10.7326/0003-4819-151-4-200908180-00135 – volume: 130 start-page: 153 issue: 3 year: 2004 end-page: 160 ident: CR85 article-title: Lack of neuroprotection by an ACTH (4–9) analogue. A randomized trial in patients treated with vincristine for Hodgkin’s or non-Hodgkin’s lymphoma publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-003-0524-9 – volume: 100 start-page: 1179 issue: 6 year: 2004 end-page: 1185 ident: CR48 article-title: Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen publication-title: Cancer doi: 10.1002/cncr.20071 – volume: 62 start-page: 1004 issue: 6 year: 2015 end-page: 1010 ident: CR83 article-title: Glutamic acid not beneficial for the prevention of vincristine neurotoxicity in children with cancer publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.25384 – volume: 64 start-page: 1076 issue: 6 year: 2005 end-page: 1077 ident: CR91 article-title: Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening publication-title: Neurology doi: 10.1212/01.wnl.0000154642.45474.28 – volume: 73 start-page: 531 issue: 6 year: 2006 end-page: 533 ident: CR15 article-title: Vincristine induced cranial polyneuropathy publication-title: Indian J Pediatr doi: 10.1007/bf02759902 – volume: 32 start-page: 594 issue: 8 year: 2010 end-page: 600 ident: CR10 article-title: A trial to assess the efficacy of glutamic acid in prevention of vincristine-induced neurotoxicity in pediatric malignancies: a pilot study publication-title: J Pediatr Hematol Oncol doi: 10.1097/MPH.0b013e3181e9038d – volume: 21 start-page: 847 issue: 3 year: 2013 end-page: 856 ident: CR33 article-title: The pediatric-modified total neuropathy score: a reliable and valid measure of chemotherapy-induced peripheral neuropathy in children with non-CNS cancers publication-title: Support Care Cancer doi: 10.1007/s00520-012-1591-8 – volume: 10 start-page: E22 issue: 2 year: 2010 end-page: E25 ident: CR77 article-title: Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma publication-title: Clin Lymphoma Myeloma Leukemia doi: 10.3816/CLML.2010.n.025 – volume: 19 start-page: 1991 issue: 12 year: 2011 end-page: 1996 ident: CR30 article-title: Burden of chemotherapy-induced neuropathy-a cross-sectional study publication-title: Support Care Cancer doi: 10.1007/s00520-010-1043-2 – volume: 1 start-page: 1251 issue: 6071 year: 1977 end-page: 1252 ident: CR23 article-title: Recurrent laryngeal nerve paralysis in patients receiving vincristine and vinblastine publication-title: BMJ doi: 10.1136/bmj.1.6071.1251 – volume: 20 start-page: 123 issue: 2 year: 1998 end-page: 124 ident: CR74 article-title: Severe vincristine toxicity in combination with itraconazole publication-title: Clin Lab Haematol doi: 10.1046/j.1365-2257.1998.00103.x – volume: 34 start-page: 1317 issue: 8 year: 2006 end-page: 1327 ident: CR107 article-title: Selective metabolism of vincristine in vitro by CYP3A5 publication-title: Drug Metab Dispos doi: 10.1124/dmd.106.009902 – volume: 73 start-page: 2515 issue: 10 year: 1994 end-page: 2519 ident: CR92 article-title: Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas publication-title: Cancer doi: 10.1002/1097-0142(19940515)73:10<2515::AID-CNCR2820731011>3.0.CO;2-G – volume: 22 start-page: 359 issue: 2 year: 2014 end-page: 366 ident: CR34 article-title: Comparison of two chemotherapy-induced peripheral neuropathy measurement approaches in children publication-title: Support Care Cancer doi: 10.1007/s00520-013-1981-6 – volume: 22 start-page: 76 issue: 1 year: 2016 end-page: 81 ident: CR64 article-title: The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia publication-title: J Oncol Pharm Pract doi: 10.1177/1078155214553143 – volume: 132 start-page: 717 issue: 5 year: 1973 end-page: 720 ident: CR27 article-title: Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone publication-title: Arch Intern Med doi: 10.1001/archinte.1973.03650110061013 – volume: 109 start-page: 4151 issue: 10 year: 2007 end-page: 4157 ident: CR56 article-title: Ancestry and pharmacogenetics of antileukemic drug toxicity publication-title: Blood doi: 10.1182/blood-2006-10-054528 – volume: 34 start-page: 292 issue: 3 year: 2011 end-page: 296 ident: CR47 article-title: Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity publication-title: Am J Clin Oncol doi: 10.1097/COC.0b013e3181e1d0c0 – volume: 313 start-page: 815 issue: 8 year: 2015 end-page: 823 ident: CR61 article-title: Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia publication-title: JAMA doi: 10.1001/jama.2015.0894 – volume: 71 start-page: 311 issue: 6 year: 1995 end-page: 312 ident: CR72 article-title: Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL publication-title: Ann Hematol doi: 10.1007/BF01697985 – year: 2017 ident: CR89 article-title: Vincristine-induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia publication-title: Pediatric Blood Cancer doi: 10.1002/pbc.26471 – volume: 14 start-page: 184 issue: 3 year: 2009 end-page: 189 ident: CR40 article-title: Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia publication-title: J Periph Nerv Syst JPNS doi: 10.1111/j.1529-8027.2009.00230.x – year: 2018 ident: CR68 article-title: Pharmacogenomics of vincristine-induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.1179 – volume: 29 start-page: 932 issue: 7 year: 2014 end-page: 937 ident: CR86 article-title: Vincristine-induced neuropathy in childhood all (acute lymphoblastic leukemia) survivors: prevalence and electrophysiological characteristics publication-title: J Child Neurol doi: 10.1177/0883073813491829 – volume: 34 start-page: e194 issue: 8 year: 2010 end-page: e196 ident: CR19 article-title: Pyridoxine treatment of vincristine-induced cranial polyneuropathy in an adult patient with acute lymphocytic leukemia: case report and review of the literature publication-title: Leuk Res doi: 10.1016/j.leukres.2010.01.026 – volume: 47 start-page: 2404 issue: 10 year: 1981 end-page: 2406 ident: CR20 article-title: Acute acoustic nerve palsy associated with vincristine therapy publication-title: Cancer doi: 10.1002/1097-0142(19810515)47:10<2404::AID-CNCR2820471014>3.0.CO;2-2 – volume: 14 start-page: 61 issue: 1 year: 1993 end-page: 75 ident: CR102 article-title: Neurotoxicity of antineoplastic agents publication-title: Crit Rev Oncol Hematol doi: 10.1016/1040-8428(93)90006-P – volume: 25 start-page: 3537 issue: 11 year: 2017 end-page: 3544 ident: CR43 article-title: Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials publication-title: Supportive Care Cancer doi: 10.1007/s00520-017-3780-y – volume: 8 start-page: 67 issue: 1 year: 2004 end-page: 68 ident: CR17 article-title: Acute sixth-nerve palsy after vincristine therapy publication-title: J AAPOS doi: 10.1016/j.jaapos.2003.07.010 – volume: 6 start-page: 252 issue: 4 year: 2014 end-page: 260 ident: CR54 article-title: Risk factors for early-onset peripheral neuropathy caused by vincristine in patients with a first administration of R-CHOP or R-CHOP-like chemotherapy publication-title: J Clin Med Res doi: 10.14740/jocmr1856w – volume: 10 start-page: 64 issue: 1 year: 2015 end-page: 66 ident: CR53 article-title: Guillain-Barre syndrome in acute lymphoblastic leukemia: causal or coincidental publication-title: J Pediatr Neurosci doi: 10.4103/1817-1745.154358 – year: 2018 ident: CR67 article-title: CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.26854 – volume: 40 start-page: e273 issue: 5 year: 2018 end-page: e277 ident: CR71 article-title: Vincristine-associated neuropathy with antifungal usage: a kaiser northern California experience publication-title: J Pediatr Hematol Oncol doi: 10.1097/MPH.0000000000001220 – volume: 12 start-page: 210 issue: 3 year: 2007 end-page: 215 ident: CR99 article-title: The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale publication-title: J Periph Nerv Syst JPNS doi: 10.1111/j.1529-8027.2007.00141.x – volume: 56 start-page: 361 issue: 3 year: 2011 end-page: 367 ident: CR59 article-title: Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.22845 – volume: 3 start-page: 315 issue: 3 year: 1985 end-page: 318 ident: CR24 article-title: Acute encephalopathy associated with continuous vincristine sulfate combination therapy: case report publication-title: Invest New Drugs doi: 10.1007/BF00179439 – volume: 52 start-page: 34 year: 2015 end-page: 37 ident: CR14 article-title: Vincristine-induced neuropathy presenting as ptosis and ophthalmoplegia in a 2-year-old boy publication-title: J Pediatr Ophthalmol Strabismus doi: 10.3928/01913913-20150629-01 – volume: 19 start-page: 9 issue: 1 year: 2012 end-page: 17 ident: CR100 article-title: Chemotherapy-induced peripheral neuropathy in pediatric cancer patients publication-title: Semin Pediatr Neurol doi: 10.1016/j.spen.2012.02.011 – volume: 95 start-page: 41 issue: 1 year: 2016 end-page: 47 ident: CR6 article-title: Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma publication-title: Ann Hematol doi: 10.1007/s00277-015-2514-9 – volume: 21 start-page: 112 issue: 6 year: 2016 end-page: 117 ident: CR25 article-title: Chemotherapy-associated posterior reversible encephalopathy syndrome: a case report and review of the literature publication-title: Neurologist doi: 10.1097/nrl.0000000000000105 – volume: 32 start-page: 407 issue: 5 year: 2010 ident: 3884_CR22 publication-title: J Pediatr Hematol Oncol doi: 10.1097/MPH.0b013e3181e01584 – volume: 34 start-page: 6731 issue: 11 year: 2014 ident: 3884_CR12 publication-title: Anticancer Res – volume: 71 start-page: 311 issue: 6 year: 1995 ident: 3884_CR72 publication-title: Ann Hematol doi: 10.1007/BF01697985 – volume: 52 start-page: 34 year: 2015 ident: 3884_CR14 publication-title: J Pediatr Ophthalmol Strabismus doi: 10.3928/01913913-20150629-01 – volume: 229 start-page: 267 issue: 4 year: 1983 ident: 3884_CR26 publication-title: J Neurol doi: 10.1007/BF00313556 – volume: 94 start-page: 1815 issue: 6 year: 2002 ident: 3884_CR28 publication-title: Cancer doi: 10.1002/cncr.10397 – volume: 11 start-page: 251 issue: 3 year: 1980 ident: 3884_CR8 publication-title: J Neurobiol doi: 10.1002/neu.480110304 – volume: 109 start-page: 4151 issue: 10 year: 2007 ident: 3884_CR56 publication-title: Blood doi: 10.1182/blood-2006-10-054528 – volume: 34 start-page: 292 issue: 3 year: 2011 ident: 3884_CR47 publication-title: Am J Clin Oncol doi: 10.1097/COC.0b013e3181e1d0c0 – volume: 14 start-page: 184 issue: 3 year: 2009 ident: 3884_CR40 publication-title: J Periph Nerv Syst JPNS doi: 10.1111/j.1529-8027.2009.00230.x – volume: 12 start-page: 210 issue: 3 year: 2007 ident: 3884_CR99 publication-title: J Periph Nerv Syst JPNS doi: 10.1111/j.1529-8027.2007.00141.x – volume: 56 start-page: 361 issue: 3 year: 2011 ident: 3884_CR59 publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.22845 – volume: 249 start-page: 9 issue: 1 year: 2002 ident: 3884_CR104 publication-title: J Neurol doi: 10.1007/PL00007853 – volume: 25 start-page: 701 issue: 3 year: 2017 ident: 3884_CR84 publication-title: Support Care Cancer doi: 10.1007/s00520-016-3441-6 – volume: 8 start-page: 69 issue: 1 year: 2004 ident: 3884_CR18 publication-title: J AAPOS doi: 10.1016/s1091853103003239 – volume: 62 start-page: 1004 issue: 6 year: 2015 ident: 3884_CR83 publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.25384 – volume: 90 start-page: 1204 issue: 10 year: 2001 ident: 3884_CR75 publication-title: Acta Paediatr doi: 10.1111/j.1651-2227.2001.tb03257.x – volume: 29 start-page: 267 issue: 3 year: 1999 ident: 3884_CR2 publication-title: Crit Rev Oncol Hematol doi: 10.1016/S1040-8428(98)00023-7 – volume: 11 start-page: 1057 issue: 11 year: 2010 ident: 3884_CR58 publication-title: Lancet Oncol doi: 10.1016/s1470-2045(10)70206-0 – volume: 32 start-page: 594 issue: 8 year: 2010 ident: 3884_CR10 publication-title: J Pediatr Hematol Oncol doi: 10.1097/MPH.0b013e3181e9038d – year: 2017 ident: 3884_CR69 publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.26525 – volume: 14 start-page: 61 issue: 1 year: 1993 ident: 3884_CR102 publication-title: Crit Rev Oncol Hematol doi: 10.1016/1040-8428(93)90006-P – volume: 100 start-page: 1179 issue: 6 year: 2004 ident: 3884_CR48 publication-title: Cancer doi: 10.1002/cncr.20071 – volume: 17 start-page: 1045 issue: 11 year: 2017 ident: 3884_CR101 publication-title: Expert Rev Anticancer Ther doi: 10.1080/14737140.2017.1374856 – volume: 29 start-page: 932 issue: 7 year: 2014 ident: 3884_CR86 publication-title: J Child Neurol doi: 10.1177/0883073813491829 – volume: 19 start-page: 1991 issue: 12 year: 2011 ident: 3884_CR30 publication-title: Support Care Cancer doi: 10.1007/s00520-010-1043-2 – volume: 64 start-page: 1076 issue: 6 year: 2005 ident: 3884_CR91 publication-title: Neurology doi: 10.1212/01.wnl.0000154642.45474.28 – volume: 52 start-page: 127 issue: 2 year: 1991 ident: 3884_CR3 publication-title: Pharmacol Ther doi: 10.1016/0163-7258(91)90004-6 – volume: 44 start-page: 1507 issue: 11 year: 2008 ident: 3884_CR103 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2008.04.018 – volume: 73 start-page: 531 issue: 6 year: 2006 ident: 3884_CR15 publication-title: Indian J Pediatr doi: 10.1007/bf02759902 – volume: 6 start-page: 252 issue: 4 year: 2014 ident: 3884_CR54 publication-title: J Clin Med Res doi: 10.14740/jocmr1856w – volume: 21 start-page: 112 issue: 6 year: 2016 ident: 3884_CR25 publication-title: Neurologist doi: 10.1097/nrl.0000000000000105 – volume: 8 start-page: 211 issue: 2 year: 1982 ident: 3884_CR46 publication-title: Cancer Chemother Pharmacol doi: 10.1007/BF00255486 – volume: 17 start-page: 731 issue: 7 year: 2016 ident: 3884_CR65 publication-title: Pharmacogenomics doi: 10.2217/pgs-2016-0001 – volume: 66 start-page: 1853 issue: 8 year: 2011 ident: 3884_CR76 publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkr223 – volume: 73 start-page: 2515 issue: 10 year: 1994 ident: 3884_CR92 publication-title: Cancer doi: 10.1002/1097-0142(19940515)73:10<2515::AID-CNCR2820731011>3.0.CO;2-G – volume: 77 start-page: 681 issue: 6 year: 2010 ident: 3884_CR82 publication-title: Indian J Pediatr doi: 10.1007/s12098-010-0096-z – volume: 15 start-page: 23 issue: 1 year: 1993 ident: 3884_CR90 publication-title: J Neurooncol doi: 10.1007/BF01050259 – volume: 22 start-page: 457 issue: 3 year: 2018 ident: 3884_CR32 publication-title: Eur J Paediatr Neurol EJPN doi: 10.1016/j.ejpn.2017.12.019 – volume: 34 start-page: e194 issue: 8 year: 2010 ident: 3884_CR19 publication-title: Leuk Res doi: 10.1016/j.leukres.2010.01.026 – volume: 26 start-page: 100 issue: 2 year: 2016 ident: 3884_CR63 publication-title: Pharmacogenet Genom doi: 10.1097/FPC.0000000000000191 – volume: 14 start-page: 45 issue: Suppl. 4 year: 2012 ident: 3884_CR105 publication-title: Neuro-oncology doi: 10.1093/neuonc/nos203 – volume: 95 start-page: 41 issue: 1 year: 2016 ident: 3884_CR6 publication-title: Ann Hematol doi: 10.1007/s00277-015-2514-9 – volume: 3 start-page: 315 issue: 3 year: 1985 ident: 3884_CR24 publication-title: Invest New Drugs doi: 10.1007/BF00179439 – volume: 36 start-page: E49 issue: 5 year: 2013 ident: 3884_CR35 publication-title: Cancer Nurs doi: 10.1097/NCC.0b013e318299ad23 – volume: 10 start-page: E22 issue: 2 year: 2010 ident: 3884_CR77 publication-title: Clin Lymphoma Myeloma Leukemia doi: 10.3816/CLML.2010.n.025 – ident: 3884_CR41 doi: 10.17724/jicna.2017.75 – volume: 25 start-page: 5121 issue: 32 year: 2007 ident: 3884_CR98 publication-title: J Clin Oncol doi: 10.1200/jco.2007.12.4784 – volume: 101 start-page: 391 issue: 3 year: 2017 ident: 3884_CR62 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.506 – volume: 132 start-page: 717 issue: 5 year: 1973 ident: 3884_CR27 publication-title: Arch Intern Med doi: 10.1001/archinte.1973.03650110061013 – volume: 21 start-page: 847 issue: 3 year: 2013 ident: 3884_CR33 publication-title: Support Care Cancer doi: 10.1007/s00520-012-1591-8 – volume: 57 start-page: 403 issue: 3 year: 2018 ident: 3884_CR50 publication-title: Acta Oncol doi: 10.1080/0284186X.2017.1415462 – volume: 49 start-page: 1027 issue: 10 year: 1992 ident: 3884_CR81 publication-title: Arch Neurol doi: 10.1001/archneur.1992.00530340043016 – year: 2017 ident: 3884_CR5 publication-title: Pharmacogenom J doi: 10.1038/s41397-017-0003-3 – volume: 47 start-page: 2404 issue: 10 year: 1981 ident: 3884_CR20 publication-title: Cancer doi: 10.1002/1097-0142(19810515)47:10<2404::AID-CNCR2820471014>3.0.CO;2-2 – volume: 313 start-page: 815 issue: 8 year: 2015 ident: 3884_CR61 publication-title: JAMA doi: 10.1001/jama.2015.0894 – volume: 25 start-page: 316 issue: 4 year: 2003 ident: 3884_CR51 publication-title: J Pediatr Hematol Oncol doi: 10.1097/00043426-200304000-00010 – volume: 29 start-page: 2728 issue: 12 year: 2006 ident: 3884_CR106 publication-title: Diabetes Care doi: 10.2337/dc06-1499 – volume: 19 start-page: 9 issue: 1 year: 2012 ident: 3884_CR100 publication-title: Semin Pediatr Neurol doi: 10.1016/j.spen.2012.02.011 – volume: 20 start-page: 123 issue: 2 year: 1998 ident: 3884_CR74 publication-title: Clin Lab Haematol doi: 10.1046/j.1365-2257.1998.00103.x – volume: 46 start-page: 160 issue: 1 year: 2002 ident: 3884_CR110 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.46.1.160-165.2002 – volume: 14 start-page: 935 issue: 3 year: 1996 ident: 3884_CR79 publication-title: J Clin Oncol doi: 10.1200/jco.1996.14.3.935 – volume: 90 start-page: 209 issue: 4 year: 1993 ident: 3884_CR16 publication-title: Acta Haematol doi: 10.1159/000204462 – volume: 7 start-page: 351 issue: 4 year: 2009 ident: 3884_CR38 publication-title: J Pediatr Neurol doi: 10.3233/JPN-2009-0333 – volume: 22 start-page: 359 issue: 2 year: 2014 ident: 3884_CR34 publication-title: Support Care Cancer doi: 10.1007/s00520-013-1981-6 – volume: 29 start-page: 62 issue: 1 year: 2012 ident: 3884_CR73 publication-title: Pediatr Hematol Oncol doi: 10.3109/08880018.2011.624163 – volume: 82 start-page: 200 issue: 1 year: 1998 ident: 3884_CR87 publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19980101)82:1<200::AID-CNCR87>3.0.CO;2-5 – volume: 11 start-page: 217 issue: 2 year: 2000 ident: 3884_CR52 publication-title: Ann Oncol doi: 10.1023/A:1008389607293 – volume: 151 start-page: 264 issue: 4 year: 2009 ident: 3884_CR31 publication-title: Ann Intern Med doi: 10.7326/0003-4819-151-4-200908180-00135 – volume: 22 start-page: 76 issue: 1 year: 2016 ident: 3884_CR64 publication-title: J Oncol Pharm Pract doi: 10.1177/1078155214553143 – volume: 41 start-page: 1135 issue: 8 year: 2005 ident: 3884_CR42 publication-title: Eur J Cancer (Oxford, England: 1990) doi: 10.1016/j.ejca.2005.02.012 – volume: 57 start-page: 1147 issue: 7 year: 2011 ident: 3884_CR44 publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.23039 – volume: 52 start-page: 981 issue: 6 year: 2015 ident: 3884_CR39 publication-title: Muscle Nerve doi: 10.1002/mus.24647 – volume: 64 start-page: 180 issue: 1 year: 2017 ident: 3884_CR96 publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.26204 – volume: 81 start-page: 146 issue: 2 year: 1976 ident: 3884_CR13 publication-title: Am J Ophthalmol doi: 10.1016/0002-9394(76)90725-X – volume: 15 start-page: 1105 issue: 8 year: 2014 ident: 3884_CR60 publication-title: Pharmacogenomics doi: 10.2217/pgs.14.68 – year: 2018 ident: 3884_CR67 publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.26854 – volume: 21 start-page: 877 issue: 9 year: 2010 ident: 3884_CR49 publication-title: Anticancer Drugs doi: 10.1097/CAD.0b013e32833db89d – volume: 1 start-page: 1251 issue: 6071 year: 1977 ident: 3884_CR23 publication-title: BMJ doi: 10.1136/bmj.1.6071.1251 – volume: 39 start-page: 266 issue: 4 year: 2017 ident: 3884_CR9 publication-title: J Pediatr Hematol Oncol doi: 10.1097/MPH.0000000000000825 – volume: 25 start-page: 3537 issue: 11 year: 2017 ident: 3884_CR43 publication-title: Supportive Care Cancer doi: 10.1007/s00520-017-3780-y – volume: 50 start-page: 769 issue: 4 year: 2008 ident: 3884_CR57 publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.21435 – volume: 14 start-page: 111 issue: 2 year: 2008 ident: 3884_CR4 publication-title: Cancer Cell doi: 10.1016/j.ccr.2008.07.002 – volume: 51 start-page: 423 issue: 3 year: 1983 ident: 3884_CR80 publication-title: Cancer doi: 10.1002/1097-0142(19830201)51:3<423::AID-CNCR2820510311>3.0.CO;2-3 – volume: 71 start-page: 63 issue: 1 year: 2007 ident: 3884_CR21 publication-title: Int J Pediatr Otorhinolaryngol doi: 10.1016/j.ijporl.2006.09.001 – volume: 130 start-page: 153 issue: 3 year: 2004 ident: 3884_CR85 publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-003-0524-9 – volume: 21 start-page: 1656 year: 2015 ident: 3884_CR1 publication-title: Med Sci Monit doi: 10.12659/MSM.893142 – volume: 8 start-page: 67 issue: 1 year: 2004 ident: 3884_CR17 publication-title: J AAPOS doi: 10.1016/j.jaapos.2003.07.010 – volume: 30 start-page: 786 issue: 6 year: 2015 ident: 3884_CR45 publication-title: J Child Neurol doi: 10.1177/0883073814535495 – volume: 34 start-page: 1317 issue: 8 year: 2006 ident: 3884_CR107 publication-title: Drug Metab Dispos doi: 10.1124/dmd.106.009902 – volume: 53 start-page: 2390 issue: 12 year: 2012 ident: 3884_CR78 publication-title: Leukemia Lymphoma doi: 10.3109/10428194.2012.697560 – volume: 1 start-page: 610 issue: 6113 year: 1978 ident: 3884_CR88 publication-title: BMJ doi: 10.1136/bmj.1.6113.610 – volume: 97 start-page: 2129 issue: 11 year: 2018 ident: 3884_CR7 publication-title: Ann Hematol doi: 10.1007/s00277-018-3437-z – volume: 47 start-page: 651 issue: 7 year: 2008 ident: 3884_CR70 publication-title: Intern Med (Tokyo, Japan) doi: 10.2169/internalmedicine.47.0701 – volume: 20 start-page: 37 issue: 1 year: 2015 ident: 3884_CR93 publication-title: J Periph Nerv Syst doi: 10.1111/jns.12114 – volume: 109 start-page: 896 issue: 3 year: 2007 ident: 3884_CR29 publication-title: Blood doi: 10.1182/blood-2006-06-027714 – year: 2018 ident: 3884_CR68 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.1179 – volume: 40 start-page: e273 issue: 5 year: 2018 ident: 3884_CR71 publication-title: J Pediatr Hematol Oncol doi: 10.1097/MPH.0000000000001220 – year: 2017 ident: 3884_CR89 publication-title: Pediatric Blood Cancer doi: 10.1002/pbc.26471 – volume: 38 start-page: 111 issue: 2 year: 2000 ident: 3884_CR109 publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200038020-00002 – volume: 64 start-page: 801 issue: 4 year: 1989 ident: 3884_CR36 publication-title: Cancer doi: 10.1002/1097-0142(19890815)64:4<801::AID-CNCR2820640406>3.0.CO;2-E – volume: 47 start-page: 207 issue: 1 year: 1981 ident: 3884_CR97 publication-title: Cancer doi: 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 – volume: 19 start-page: 1097 issue: 8 year: 2010 ident: 3884_CR94 publication-title: Q Life Res doi: 10.1007/s11136-010-9670-0 – volume: 27 start-page: 383 issue: 4 year: 2001 ident: 3884_CR108 publication-title: Nat Genet doi: 10.1038/86882 – volume: 27 start-page: 286 issue: 5 year: 2005 ident: 3884_CR11 publication-title: J Pediatr Hematol Oncol doi: 10.1097/01.mph.0000165130.21539.a3 – volume: 10 start-page: 64 issue: 1 year: 2015 ident: 3884_CR53 publication-title: J Pediatr Neurosci doi: 10.4103/1817-1745.154358 – volume: 152 start-page: 115 issue: 2 year: 1993 ident: 3884_CR95 publication-title: Eur J Pediatr doi: 10.1007/BF02072486 – volume: 122 start-page: 240 issue: 2 year: 2003 ident: 3884_CR55 publication-title: Br J Haematol doi: 10.1046/j.1365-2141.2003.04430.x – volume: 45 start-page: 355 issue: 2–3 year: 1980 ident: 3884_CR37 publication-title: J Neurol Sci doi: 10.1016/0022-510X(80)90179-3 – volume: 39 start-page: 458 issue: 6 year: 2017 ident: 3884_CR66 publication-title: J Pediatr Hematol Oncol doi: 10.1097/mph.0000000000000910 |
| SSID | ssj0004133 |
| Score | 2.5612276 |
| SecondaryResourceType | review_article |
| Snippet | Purpose
Vincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive... Vincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive vincristine-induced... PurposeVincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 471 |
| SubjectTerms | Antineoplastic Agents, Phytogenic - adverse effects Autonomic nervous system Blood cancer Cancer Research Central nervous system Drug-Related Side Effects and Adverse Reactions - etiology Drug-Related Side Effects and Adverse Reactions - pathology Fluconazole Hematologic Neoplasms - drug therapy Hematologic Neoplasms - pathology Humans Itraconazole Medicine Medicine & Public Health Neurotoxicity Neurotoxicity Syndromes - etiology Neurotoxicity Syndromes - pathology Oncology Peripheral neuropathy Pharmacodynamics Pharmacokinetics Pharmacology/Toxicology Prognosis Quality of life Review Review Article Reviews Vincristine Vincristine - adverse effects Voriconazole |
| SummonAdditionalLinks | – databaseName: Public Health Database dbid: 8C1 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEB5BixAXWsLLtKBFQr2QFX6sH9tLVVVUXKhyKFLExdqXSyRwSpxUyr9n9hFboWovvXo3tjfz9sx8A_BJZEWDfqukMpOKopYUtFK2BIqXhjeVtdDaDZsoLy6q6ZRPwge3LpRVbnSiU9R6ruw38i-pt91ZzE-u_1I7NcpmV8MIjcewm6Qxs4JZnQ0lHvhoPx6ZMZqXMQtNM651zuUUMZDm1OKh4Pq2Ybrlbd4umvwvc-oM0vneQ4-yD8-DK0pOPe-8gEemHcHT7yHZPoKjiYe1Xo_J5dCl1Y3JEZkMgNfrl_Dz1PVrdmTekJtZq5zeaA3FcB8ZRxOHmWlHH6_JrCUOJdarXPIHo4ArPyC4OyaCDLjSxPfUvIIf518vz77RMLOBKvT9llQZpi1YUq6zJJVJg8SOhc6TQtrI0wLhxkZqUYmYiYYbncaaG8EUL4yMc51mr2GnnbfmLZAKfTeN1yrGE9ZUjcyL0khZYoRWJrwRESQbgtUqAJrbuRq_6x6K2RG5RiLXjsh1HsHn_jfXHs7j3t2HGwLWQbS7eqBeBB_7ZRRKm2kRrZmv3J7MvnWaRfDGs03_OPxfEoYmKIJyi6H6DRbwe3ulnf1ywN9FgfF8ifccb1hveK27T_Hu_lMcwLPUiYGtmzuEneViZd7DE3WznHWLD06g_gEOHiaO priority: 102 providerName: ProQuest |
| Title | Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review |
| URI | https://link.springer.com/article/10.1007/s00280-019-03884-5 https://www.ncbi.nlm.nih.gov/pubmed/31214762 https://www.proquest.com/docview/2242644309 https://www.proquest.com/docview/2243491423 https://pubmed.ncbi.nlm.nih.gov/PMC6682573 |
| Volume | 84 |
| WOSCitedRecordID | wos000478903100002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1432-0843 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004133 issn: 0344-5704 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB7RFiEuPMorUFZGQr2wluK8bHMrVSsurFaloBWXyI6dshJkUbOttP-esZ2HlgISXHKIJ44fY8-MZuYbgNcqLWrUWzXVqa4o3pKKisqFQEluZS2chDa-2ASfzcRiIeddUljbR7v3Lkl_Uw_Jbt4LiKavpA7BJKP5DuyhuBPuOJ59_DxmQ7JQQD7NkIbHWZcq8_s-tsXRDR3zZqjkL_5SL4ZO7__fBB7AvU7tJEeBTx7CLdvsw50PnWN9Hw7nAcJ6MyXnY0ZWOyWHZD6CW28ewZcjn5vZklVNrpdN5e-IxlI07ZFJDPH4mK7M8YYsG-IRYcP1Sr6jxn8RigG3b4kiI4Y0Cfkzj-HT6cn58Xva1WegFep5a1rZzDhgpNykLNGsxo2NlclZoZ2V6UBvY6uNEirOVC2tSWIjrcoqWVgd5yZJn8Bus2rsMyAC9TSD70QmWVaLWucFt1pztMY4k7WKgPXbVFYdeLmrofGtHGCX_eqWuLqlX90yj-DN8M2PAN3xV-qDfvfL7hi3ZRIUxjSWEbwamvEAOq-KauzqytOkbtRJGsHTwCzD73BdWIbiJgK-xUYDgQP33m5pll89yHdRoO3Osc9pz0zjsP48i-f_Rv4C7iaeH13M3AHsri-v7Eu4XV2vl-3lBHb4gvunwKc4ZhPYe3cym59N_IH7CV0kITE |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LbxMxEB5VBUEvPMproYCRoBdisW-vkRCqgKpV2yiHIEVcFnvtLSvBpnTTovwpfiNjex8KFb31wDX2JrbzzWs98w3ASxGlJfqtkspIFhS1pKBZYVKgONO8zIyFVrbZBBuPs9mMT9bgd1cLY9IqO51oFbWaF-Yd-ZvQ2e7I5-9PflLTNcrcrnYtNBwsDvTyF4Zszbv9j_j_vgrD3U_TD3u07SpAC_ROFrTQsTJ0PomKglAGJS7HFyoJUmliI0PV6mupRCb8WJRcq9BXXIu44KmWfqIM0QGq_Guox5lJIWMzNtRhBq51fRTHNGF-3Bbp2FI9e4eJgTunhn8Fx1cN4QXv9mKS5l83tdYA7t7-347uDtxqXW2y42TjLqzpehNuHLXJBJuwPXG03csRmQ5VaM2IbJPJQOi9vAdfdmw9akPmJTmv6sLqxVrTqlYoGIpYTlDT2nlJqppYFlxnUsgPjHKOXQPk5i0RZODNJq5m6D58vpIjeADr9bzWj4Bk6Jsq_CyLeRCXWSmTlGkpGUagLOCl8CDoAJIXLWG76RvyPe-ppi2ocgRVbkGVJx687p85cXQll87e6gCTt6qryQe0ePCiH0alY26SRK3nZ3ZOZFYdRh48dDDtfw7PJYjRxHrAVgDcTzCE5qsjdfXNEpunaYYWBL9z1EF9WNa_d_H48l08h5t706PD_HB_fPAENkIrgiZHcAvWF6dn-ilcL84XVXP6zAozga9XLQJ_AMeOg5U |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LbxMxEB5VBVVceJTXQgEjQS_E6r69RkKookRUhSiHIkVctvbaS1cqm9JNi_LX-HWM7X0oVPTWA9fYm9jON6_1zDcAr0SUlui3SiojWVDUkoJmhUmB4kzzMjMWWtlmE2wyyWYzPl2D310tjEmr7HSiVdRqXph35Duhs92Rz3fKNi1iujd-f_qTmg5S5qa1a6fhIHKgl78wfGve7e_hf_06DMcfDz98om2HAVqgp7KghY6VofZJVBSEMihxab5QSZBKEycZ2lZfSyUy4cei5FqFvuJaxAVPtfQTZUgPUP3fYFHETNsINmNDTWbg2thHcUwT5sdtwY4t27P3mRjEc2q4WHB81She8nQvJ2z-dWtrjeH4zv98jHfhduuCk10nM_dgTdebsPGlTTLYhO2po_NejsjhUJ3WjMg2mQ5E38v78G3X1qk2ZF6Si6ourL6sNa1qhQKjiOUKNS2fl6SqiWXHdaaG_MDo57trjNy8JYIMfNrE1RI9gK_XcgQPYb2e1_oxkAx9VoWfZTEP4jIrZZIyLSXDyJQFvBQeBB1Y8qIlcjf9RE7ynoLaAixHgOUWYHniwZv-mVNHY3Ll7K0OPHmr0pp8QI4HL_thVEbmhknUen5u50Rm1WHkwSMH2f7n8FyCGE2vB2wFzP0EQ3S-OlJXx5bwPE0ztCz4naMO9sOy_r2LJ1fv4gVsIPLzz_uTg6dwK7TSaFIHt2B9cXaun8HN4mJRNWfPrVwTOLpuCfgDw3yMSQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Aspects+of+vincristine-induced+neuropathy+in+hematologic+malignancies%3A+a+systematic+review&rft.jtitle=Cancer+chemotherapy+and+pharmacology&rft.au=Madsen%2C+Marie+Lindhard&rft.au=Due%2C+Hanne&rft.au=Ejskj%C3%A6r%2C+Niels&rft.au=Jensen%2C+Paw&rft.date=2019-09-01&rft.pub=Springer+Berlin+Heidelberg&rft.issn=0344-5704&rft.eissn=1432-0843&rft.volume=84&rft.issue=3&rft.spage=471&rft.epage=485&rft_id=info:doi/10.1007%2Fs00280-019-03884-5&rft.externalDocID=10_1007_s00280_019_03884_5 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0344-5704&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0344-5704&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0344-5704&client=summon |